Title: The Extent to Which Diclofenac is used to Treat Fever Cases of Children and the Elderly in the Emergency Department of Governmental and Private Hospitals in Amman
Author: Jafar Mohammad Ahmad Yasin
DOI: https://dx.doi.org/10.18535/jmscr/v9i12.01
Abstract
This study was conducted to investigate the rate of usage of Diclofenac in the treatment of children and the elderly by doctors compared to other fever treatment drugs in the EDs of governmental and private hospitals in Amman- Jordan.
Procedures: A survey of 126 patients in the 12-60 age groups who attended to hospitals EDs to get treatment for fever cases and investigated the use of Diclofenac treatment in the treatment of these cases or other fever treatment drugs were used, from August 2021 to October 2021 in governmental and private hospitals in Amman- Jordan.
Results: In this study, the usage of Diclofenac in the treatment of fever cases was noticed at an rate of 89% compared to other fever treatment drugs in private hospitals, and of average of 38% compared to other fever treatment drugs in governmental hospitals, due to the financial expenses of the drug compared to other fever treatment drugs and the amount of quantities available for usage in the hospital itself.
Conclusion: The researcher recommends expanding the scope of the study sample to study and analyze a larger sample, which will lead to better access to Diclofenac and greater satisfaction scores than patients attending treatment in the emergency departments of these hospitals.
References
- Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat N Biol. 1971;231(25):232–5.
- Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80(4B):18–23.
- Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108(1):7–13.
- Smyth EM, Grosser T, Wang M, Yu Y, Fitz Gerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50 (Suppl): S423–8.
- Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15.
- Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271(3):1705–12.
- Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3–4):317–27.
- Huntjens D, Danhof M, Della Pasqua O. Pharmacokinetic–pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology. 2005;44(7):846–59.
- Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–36.
- Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci. 1999;96(13):7563–8.
- Altman, R., Bosch, B., Brune, K. et al. Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. Drugs 75, 859–877 (2015).